

I claim:

1. A method of detecting HPV-induced cell transformation in a patient infected with HPV comprising the steps of:
 - measuring HPV-expressed mRNA levels from a sample collected from said patient, said mRNAs comprising one or more of E6 mRNA, E7 mRNA, E2 mRNA, E1 mRNA, E4 mRNA, L2 mRNA and L1 mRNA;
 - determining expression level of E6 and/or E7 and expression level of E2 and/or L1 such that a ratio of E6 and/or E7 to L1 and/or E2 is determined, wherein a ratio of greater than 2 is indicative of HPV-induced cell transformation and risk of neoplasia.
2. A method of predicting the onset of HPV-induced cancer in a patient infected with HPV comprising the steps of:
 - measuring a group I and a group II and/or a group III HPV mRNA from a sample collected from said patient;
 - determining ratio of group I mRNA level to group II and/or group III mRNA level wherein a ratio of greater than 2 is indicative of neoplastic onset.
3. A method of monitoring stage of HPV-induced disease in a patient infected with HPV comprising the steps of:
 - measuring HPV-expressed mRNA levels from a sample collected from said patient;
 - determining expression level of E6 and/or E7 and expression level of E2 and/or L1; and
 - determining a ratio of E6 and/or E7 expression level to L1 and/or E2 expression level wherein a ratio of greater than 2 is indicative of neoplastic change.

4. A method of detecting HPV-induced cancer in a patient infected with HPV comprising the steps of:
- measuring HPV-expressed mRNA levels from a sample collected from said patient, said mRNAs comprising one or more of E6 mRNA, E7 mRNA, E2 mRNA and L1 mRNA;
 - determining expression level of E6 and/or E7 and expression level of E2 and/or L1 such that a ratio of E6 and/or E7 to L1 and/or E2 is determined, wherein a ratio of greater than 4 is indicative of HPV-induced cancer.
5. A method of predicting the risk or onset of HPV-induced cancer in a patient infected with HPV comprising the steps of:
- measuring a group I and a group II and/or a group III HPV mRNA from a sample collected from said patient;
 - determining ratio of group I mRNA level to group II and/or group III mRNA level wherein a ratio of greater than 4 is indicative of HPV-induced cancer onset.
6. A kit comprising at least two probes capable of detecting HPV RNA, wherein at least one probe is selected from the group consisting of E2, E4, E6 and E7, and at least one probe is selected from the group consisting of L1, L2, E1, E2, E4, and E5.
7. The kit according to claim 6, wherein at least one probe is a DNA probe.

TOP SECRET - 44702660